Revvity is targeting one of biotech’s biggest early-stage challenges — building powerful digital infrastructure without slowing scientific progress.

 

This, with the launch of “Signals for Startups,” a new program designed to help emerging biotechnology companies establish scalable informatics foundations from day one.

 

The initiative, launched through Revvity Signals Software, gives early-stage biotechs access to enterprise-grade Signals software combined with guided onboarding and startup-focused configurations designed to accelerate adoption, improve collaboration and help research teams move discoveries forward faster.

 

As young biotech companies race to advance programs with limited IT, informatics and operational resources, many face growing data complexity and fragmented workflows that can create roadblocks later. 

 

Signals for Startups aims to tackle those challenges by providing ready-to-use environments and workflows tailored for both large- and small-molecule research.

 

"Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale,” said Kevin Willoe, president of Revvity Signals Software. 

 

“By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.”

 

The program offers bundled licenses with a pathway for expansion as companies progress from seed-stage operations through venture funding and later growth phases. Revvity said the approach is designed to help startups avoid disconnected systems, inconsistent data practices and costly workflow changes as research efforts mature.